Unigene Laboratories, Inc. (OTCBB: UGNE) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin Phase III studies for osteoporosis and osteoarthritis. Its recommendation is based on the committee’s recently completed “futility” analysis of the data obtained from all patients enrolled for at least twelve months in these studies. That analysis included an assessment of both safety and efficacy parameters…

See the original post here:
Independent Advisory Committee Recommends Continuation Of Phase III Oral Calcitonin Studies For Osteoporosis And Osteoarthritis

Popularity: 1%

You may also like:

• BioAlliance Pharma: Breakthrough Positive Phase III Results With Acyclovir Lauriad(R) Primary And Secondary Endpoints Met - Final Results
• Independent Advisory Committee Recommends Continuation Of Phase III Oral Calcitonin Studies For Osteoporosis And Osteoarthritis
• Amgen Receives CHMP Positive Opinion For Prolia(TM) (Denosumab) In The European Union
• Aptuit Publishes Study Which Demonstrates The Value Of Early Insights Into The Characterization Of Drug Compounds
• Aptuit Publishes Study Which Demonstrates The Value Of Early Insights Into The Characterization Of Drug Compounds
• GSK Receives Positive Opinions In Europe For Tyverb® (lapatinib) And Votrient™ (pazopanib)
• EKOS Corporation Announces Clinical Study For The Treatment Of Pulmonary Embolism Using The EKOS EkoSonic(R) Endovascular Device
• Research Published By Standard Process Inc. Scientists About The Effects Of Dietary Intervention On Cholesterol Levels
• BioAlliance Pharma: Breakthrough Positive Phase III Results With Acyclovir Lauriad(R) Primary And Secondary Endpoints Met - Final Results
• Nycomed Announces FDA Filing For Daxas(R) In COPD